HealthEquity (NASDAQ:HQY) Price Target Raised to $107.00

HealthEquity (NASDAQ:HQY) had its target price raised by investment analysts at JMP Securities from $105.00 to $107.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. JMP Securities’ price target would indicate a potential upside of 12.14% from the company’s current price.

A number of other brokerages also recently issued reports on HQY. BTIG Research boosted their price objective on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. The Goldman Sachs Group began coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 price objective for the company. Deutsche Bank Aktiengesellschaft lifted their target price on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Bank of America increased their price target on HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Mizuho assumed coverage on HealthEquity in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $110.71.

HealthEquity Stock Performance

HQY stock traded down $5.58 during midday trading on Tuesday, reaching $95.42. 587,150 shares of the company’s stock traded hands, compared to its average volume of 627,664. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity has a 52-week low of $62.10 and a 52-week high of $105.82. The stock has a market cap of $8.33 billion, a P/E ratio of 79.52, a PEG ratio of 1.57 and a beta of 0.55. The stock’s 50-day moving average is $92.81 and its 200 day moving average is $83.79.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the sale, the director now owns 54,719 shares in the company, valued at $4,540,582.62. This trade represents a 13.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Frank Corvino sold 1,039 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the transaction, the director now owns 3,784 shares in the company, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,536 shares of company stock worth $884,517 over the last ninety days. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

Several large investors have recently added to or reduced their stakes in HQY. Wasatch Advisors LP raised its stake in shares of HealthEquity by 6.6% during the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock valued at $635,065,000 after acquiring an additional 483,269 shares in the last quarter. Mackenzie Financial Corp raised its position in HealthEquity by 16.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock valued at $203,822,000 after purchasing an additional 325,906 shares in the last quarter. Generate Investment Management Ltd purchased a new stake in shares of HealthEquity in the 2nd quarter worth $24,184,000. Vaughan Nelson Investment Management L.P. lifted its holdings in shares of HealthEquity by 36.7% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock worth $69,034,000 after buying an additional 226,563 shares during the period. Finally, Thrivent Financial for Lutherans grew its position in shares of HealthEquity by 924.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 220,220 shares of the company’s stock worth $18,983,000 after buying an additional 198,718 shares in the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.